Zobrazeno 1 - 10
of 121
pro vyhledávání: '"V. Hernández Hernández"'
Tocilizumab‐related hypertriglyceridemia is independent of key molecules regulating lipid metabolism
Autor:
Iván Ferraz‐Amaro, Sergio Santos‐Concepción, Javier Castro, María V. Hernández‐Hernández, Beatriz Tejera‐Segura, Cristina Luna, Esmeralda Delgado‐Frias, Federico Díaz‐González
Publikováno v:
European Journal of Clinical Investigation.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::619839061198839b9c532ff064f8b7d7
https://doi.org/10.1111/eci.14006
https://doi.org/10.1111/eci.14006
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Fernanda Genre, M. A. González-Gay, V. Hernández-Hernández, María Teresa García-Unzueta, B. Lavín-Gómez, Alejandra González-Delgado, Iván Ferraz-Amaro, N. Fañanas-Rodríguez, Alfonso Corrales, Esmeralda Delgado-Frías, Juan Carlos Quevedo-Abeledo, L. De Armas-Rillo, J Rueda-Gotor, A. de Vera-González
Publikováno v:
Scandinavian Journal of Rheumatology. 49:476-483
Objectives: Insulin resistance (IR) constitutes a major underlying abnormality driving cardiovascular disease in the general population and has been linked to inflammatory diseases. In this study, we aimed to determine the prevalence of IR in patient
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::316154e7fb733c21d6cd67c8b48982d2
https://doi.org/10.1080/03009742.2020.1751272
https://doi.org/10.1080/03009742.2020.1751272
Publikováno v:
Polibotánica.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::36a2a6519c046ecf4b24e8ab4099aac1
https://doi.org/10.18387/polibotanica.53.4
https://doi.org/10.18387/polibotanica.53.4
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
J. T. Sánchez-Costa, I. Hernández, E. Fernández-Fernández, M. T. Silva, J. A. Valero Jaimes, I. González Fernández, J. Sanchez-Martin, J. Lluch Pons, E. Galíndez-Agirregoikoa, J. Mendizabal, P. Lois, J. Loricera, A. Muñoz Jimenez., C. Valero, P. Moya, C. Larena, V. A. Navarro Angeles, J. Calvet, I. Casafont-Solé, F. Ortiz-Sanjuán, S. Labrada, J. Calvo, C. L. Iñíguez, V. Hernández Hernández, C. Campos Fernández, M. Alcalde Villar, A. J. Mas, E. De Miguel, J. Narváez, M. A. González-Gay, N. P. Garrido Puñal, P. Estrada, R. Blanco
Publikováno v:
Annals of the Rheumatic Diseases. 81:686.1-686
BackgroundGlucocorticoids (GC) are the mainstay therapy in Giant Cell Arteritis (GCA), initially at high doses (40-60 mg/day) followed by gradual glucocorticoid tapering. This treatment, especially in older patients, is associated with numerous adver
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f869bafd885fcb6656beb6c7b198c530
https://doi.org/10.1136/annrheumdis-2022-eular.1314
https://doi.org/10.1136/annrheumdis-2022-eular.1314
Autor:
S. Remuzgo-Martínez, J. Rueda-Gotor, V. Pulito-Cueto, R. López-Mejías, A. Corrales, L. Lera-Gómez, R. Pérez-Fernández, V. Portilla, I. Gonzalez-Mazon, R. Blanco, R. Expósito, C. Mata, J. Llorca, V. Hernández-Hernández, C. Rodríguez-Lozano, N. Barbarroja Puerto, R. Ortega Castro, E. F. Vicente-Rabaneda, C. Fernández-Carballido, M. P. Martínez-Vidal, D. Castro-Corredor, J. Anino-Fernández, D. Peiteado, C. Plasencia, E. Galindez, M. L. García Vivar, N. Vegas-Revenga, I. Urionaguena, O. Gualillo, J. C. Quevedo-Abeledo, S. Castañeda, I. Ferraz-Amaro, M. A. González-Gay, F. Genre
Publikováno v:
Annals of the Rheumatic Diseases. 81:414.1-415
BackgroundAxial spondyloarthritis (axSpA) is an inflammatory disease with detrimental effects on the health status of the individuals affected by this condition [1]. axSpA patients also exhibit high cardiovascular (CV) risk, mainly due to accelerated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::45300480d52813b069e57cbc30fe0cee
https://doi.org/10.1136/annrheumdis-2022-eular.1058
https://doi.org/10.1136/annrheumdis-2022-eular.1058
Autor:
C. Almeida, J. C. Quevedo-Abeledo, L. Cáceres Martín, V. Hernández Hernández, A. Delgado-González, I. Ferraz-Amaro
Publikováno v:
Annals of the Rheumatic Diseases. 81:1166.3-1166
BackgroundThe interleukin-1 receptor antagonist (IL1-Ra) belongs to the IL-1 family. IL1-Ra has an inhibitory function on the inflammatory reaction consisting of preventing the binding of IL-1α and β to their respective receptors. IL-1, in its diff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4d1150ac44bfac66538ff86f7c5883a4
https://doi.org/10.1136/annrheumdis-2022-eular.1625
https://doi.org/10.1136/annrheumdis-2022-eular.1625
Autor:
S. Santos-Concepción, J. Castro-Hernández, V. Hernández-Hernández, C. Luna-Gomez, I. Ferraz-Amaro, F. Diaz-Gonzalez
Publikováno v:
Annals of the Rheumatic Diseases. 81:576.2-577
BackgroundTocilizumab is a humanized immunoglobulin G antibody to the interleukin 6 (IL-6) receptor that is used in the treatment of patients with rheumatoid arthritis (RA). Patients receiving TCZ are more likely to experience an elevation in total c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b74b2bd8251fd0e27b8df643229ca484
https://doi.org/10.1136/annrheumdis-2022-eular.3577
https://doi.org/10.1136/annrheumdis-2022-eular.3577